LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Viatris Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
Transcript : Viatris Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 08:00 AM
Viatris Inc. Appoints Rogerio Vivaldi Coelho to Board of Directors CI
IQuest Enterprises Private Limited acquired API operations of Viatris in India. CI
Transcript : Viatris Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing MT
UBS Trims Viatris Price Target to $12 From $13, Maintains Neutral Rating MT
Transcript : Viatris Inc., Q1 2024 Earnings Call, May 09, 2024
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. CI
Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024 CI
Viatris Inc. Revises Earnings Guidance for the Year 2024 CI
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced MT
(VTRS) VIATRIS Forecasts Fiscal Year 2024 Revenue Range $14.98B - $15.48B MT
Earnings Flash (VTRS) VIATRIS Posts Q1 Revenue $3.66B, vs. Street Est of $3.69B MT
Earnings Flash (VTRS) VIATRIS Reports Q1 EPS $0.67, vs. Street Est of $0.67 MT
Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
China trade heats up, UK rates in view RE
Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal MT
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada MT
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer CI
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc CI
UK's Theramex sees no impact to HRT products supply after CMA probe RE
Chart Viatris Inc.
More charts
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates approximately 30 manufacturing sites worldwide that produce oral solid doses, injectables and complex dosage forms.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
10.47 USD
Average target price
12.4 USD
Spread / Average Target
+18.40%
Consensus
  1. Stock Market
  2. Equities
  3. VTRS Stock
  4. News Viatris Inc.
  5. Sector Update: Health Care Stocks Lower Late Afternoon